Abstract
Background
Chronic intraprostatic inflammation is suspected to play a major role in the pathogenesis of prostate cancer (PCa). Polymorphisms in interleukin-10 (IL-10), a key anti-inflammatory cytokine gene can influence immune response and immune evasion of tumor cells. Its role as an anti-metastatic molecule is also well documented.
Methods
Gene promoter polymorphisms in IL-10 (−1082 G>A and −819 C>T) was analyzed in 159 PCa patients and 259 healthy controls to investigate their potential association with susceptibility for PCa.
Results
Our results indicated that the heterozygous (GA) and homozygous mutant (AA) genotypes of IL-10 −1082 to be more prevalent among PCa patients in comparison to controls (GA: OR − 2.8, p = 0.011; AA: OR − 2.3, p = 0.037). More patients (92.5%) than controls (82.7%) were positive for the A allele (GA + AA: OR − 2.6, p = 0.015). We observed lower frequency of T(−819)-G(−1082) haplotype in patients without bone metastasis (4.4%, OR − 0.30, p = 0.019) in comparison to PCa patients with bone metastasis (12.6%).
Conclusion
Our results support the emerging hypothesis that genetically determined immune activity may play a role in the pathophysiology of PCa. Our findings of high producer of IL-10 −1082 variants suggest initiation of PCa. Future studies in large cohort of different ethnicity PCa groups are warranted to establish definite associations with other cytokine gene polymorphisms.
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
Kolonel LN, Nomura AM, Cooney RV (1999) Dietary fat and prostate cancer: current status. J Natl Cancer Inst 91:414–428. doi:10.1093/jnci/91.5.414
Hickey K, Do KA, Green A (2001) Smoking and prostate cancer. Epidemiol Rev 23:115–125
De Marzo AM, Platz EA, Sutcliffe S (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256–269. doi:10.1038/nrc2090
Lichenstein P, Holm N, Verkasalo P et al (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78–85. doi:10.1056/NEJM200007133430201
Hayes RB (2001) Gene-environment interrelations in prostate cancer. Epidemiol Rev 23:163–167
Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13–27. doi:10.1016/S0065-230X(04)92002-7
Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–76. doi:10.1016/j.cytogfr.2003.11.001
Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA (2008) Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19:119–124. doi:10.1007/s10552-007-9077-6
Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM (2000) Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44:271–274. doi:10.1002/1097-0045(20000901)44:4<271::AID-PROS2>3.0.CO;2-G
Spits H, De Waal Malefyt R (1992) Functional characterization of human IL-10. Int Arch Allergy Immunol 99:8–15
Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8
Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64
Kesarwani P, Singh R, Mittal RD (2008) Association of GSTM3 Intron 6 variant with cigarette smoking, tobacco chewing and alcohol as modifier factors for prostate cancer risk. Arch Toxicol. doi:10.1007/s00204-008-0343-5
Miller SA, Dykes DD, Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215–1215. doi:10.1093/nar/16.3.1215
Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV (1999) ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 7:127–128. doi:10.1016/S0966-3274(99)80030-6
Zheng LM, Ojcius DM, Garaud F et al (1996) Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184:579–584. doi:10.1084/jem.184.2.579
de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209–1220. doi:10.1084/jem.174.5.1209
Fortis C, Foppoli M, Gianotti L et al (1996) Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 104:1–5b. doi:10.1016/0304-3835(96)04213-9
McCarron SL, Edwards S, Evans PR et al (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369–3372
Sredni B, Weil M, Khomenok G (2004) Ammonium trichloro(dioxoethylene-o, o′)tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 64:1843–1852. doi:10.1158/0008-5472.CAN-03-3179
Stearns ME, Fudge K, Garcia F, Wang M (1997) IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17(2):62–74
Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915–3922
Eder T, Mayer R, Langsenlehner U et al (2007) Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 43:472–475. doi:10.1016/j.ejca.2006.11.003
Andersson SO, Baron J, Bergström R, Lindgren C, Wolk A, Adami HO (1996) Lifestyle factors and prostate cancer risk: a case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 5:509–513
Meliska CJ, Stunkard ME, Gilbert DG et al (1995) Immune function in cigarette smokers who quit smoking for 31 days. J Allergy Clin Immunol 95:901–910. doi:10.1016/S0091-6749(95)70135-4
Acknowledgments
The work was supported by Department of Science and Technology, New Delhi. The authors are thankful to Dr. Anil Mandhani (Department Of Urology) and senior residents of Department of Urology for recruitment of patients and organising health check-up camps from time to time which was helpful in collecting healthy controls. PK is thankful to Indian Council of Medical Research, New Delhi and DKA is thankful to Department of Biotechnology, New Delhi, for Senior Research Fellowship.
Conflict of interest statement
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kesarwani, P., Ahirwar, D.K., Mandhani, A. et al. IL-10 −1082 G>A: a risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort. World J Urol 27, 389–396 (2009). https://doi.org/10.1007/s00345-008-0361-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-008-0361-1